Wild-Type Transthyretin Cardiac Amyloidosis: Novel Insights From Advanced Imaging

Canadian Journal of Cardiology

Volumn 32, Issue 9, 2016, Pages 1166.e1-1166.e10

  Narotsky, David L ^a   Castano, Adam ^a   Weinsaft, Jonathan W ^b   Bokhari, Sabahat ^a   Maurer, Mathew S ^a  

^a Department of Medicine   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; PREALBUMIN;

BLOOD VESSEL PARAMETERS; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR SYSTEM EXAMINATION; DIAGNOSTIC IMAGING; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEART AMYLOIDOSIS; HEART CONTRACTION; HEART FUNCTION; HEART MUSCLE BIOPSY; HUMAN; NUCLEAR SCINTIGRAPHY; PROGNOSIS; REVIEW; SCINTIGRAPHY; T1 MAPPING; WALL THICKNESS; ALGORITHM; AMYLOID NEUROPATHIES, FAMILIAL; CARDIOMYOPATHIES; PROCEDURES;

ALGORITHMS; AMYLOID NEUROPATHIES, FAMILIAL; CARDIOMYOPATHIES; DIAGNOSTIC IMAGING; ELECTROCARDIOGRAPHY; HUMANS; MYOCARDIAL CONTRACTION; PROGNOSIS;

EID: 84991737607     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2016.05.008     Document Type: Review

References (53)

1. 1 Rapezzi, C., Lorenzini, M., Longhi, S., et al. Cardiac amyloidosis: the great pretender. Heart Fail Rev 20 (2015), 117–124.
2. 2 Rapezzi, C., Merlini, G., Quarta, C.C., et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 120 (2009), 1203–1212.
3. 3 Bejar, D., Colombo, P.C., Latif, F., Yuzefpolskaya, M., Infiltrative cardiomyopathies. Clin Med Insights Cardiol 9:suppl 2 (2015), 29–38.
4. 4 Falk, R.H., Quarta, C.C., Dorbala, S., How to image cardiac amyloidosis. Circ Cardiovasc Imaging 7 (2014), 552–562.
5. 5 Mohty, D., Damy, T., Cosnay, P., et al. Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis 106 (2013), 528–540.
6. 6 Jacobson, D.R., Alexander, A.A., Tagoe, C., Buxbaum, J.N., Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans. Amyloid 22 (2015), 171–174.
7. 7 Banypersad, S.M., Moon, J.C., Whelan, C., Hawkins, P.N., Wechalekar, A.D., Updates in cardiac amyloidosis: a review. J Am Heart Assoc, 1, 2012, e000364.
8. 8 González-López, E., Gallego-Delgado, M., Guzzo-Merello, G., et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36 (2015), 2585–2594.
9. 9 Mohammed, S.F., Mirzoyev, S.A., Edwards, W.D., et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2 (2014), 113–122.
10. 10 Aljaroudi, W.A., Desai, M.Y., Tang, W.H., et al. Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques. J Nucl Cardiol 21 (2014), 271–283.
11. 11 Di Bella, G., Pizzino, F., Minutoli, F., et al. The mosaic of the cardiac amyloidosis diagnosis: role of imaging in subtypes and stages of the disease. Eur Heart J Cardiovasc Imaging 15 (2014), 1307–1315.
12. 12 Ruberg, F.L., Maurer, M., Judge, D., et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J 64 (2012), 222–228.
13. 13 Connors, L.H., Sam, F., Skinner, M., et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation 133 (2016), 282–290.
14. 14 Coelho, T., Maia, L.F., Martins da Silva, A., et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79 (2012), 785–792.
15. 15 Berk, J.L., Suhr, O.B., Obici, L., et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 310 (2013), 2658–2667.
16. 16 Castano, A., Drachman, B.M., Judge, D., Maurer, M.S., Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev 20 (2015), 163–178.
17. 17 Rubinow, A., Skinner, M., Cohen, A.S., Digoxin sensitivity in amyloid cardiomyopathy. Circulation 63 (1981), 1285–1288.
18. 18 Falk, R.H., Diagnosis and management of the cardiac amyloidoses. Circulation 112 (2005), 2047–2060.
19. 19 Cyrille, N.B., Goldsmith, J., Alvarez, J., Maurer, M.S., Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol 114 (2014), 1089–1093.
20. 20 Okin, P.M., Wright, J.T., Nieminen, M.S., et al. Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE Study. Am J Hypertens 15 (2002), 663–671.
21. 21 Quarta, C.C., Perlini, S., Longhi, S., et al. A simple voltage/mass index improves diagnosis of cardiac amyloidosis: an electrocardiographic and echocardiographic study of 570 patients with left ventricular hypertrophy (abstract). J Am Coll Cardiol, 59(13 suppl 1), 2012, E1586.
22. 22 Bokhari, S., Shahzad, R., Castaño, A., Maurer, M.S., Nuclear imaging modalities for cardiac amyloidosis. J Nucl Cardiol 21 (2014), 175–184.
23. 23 Linke, R.P., On typing amyloidosis using immunohistochemistry: detailed illustrations, review and a note on mass spectrometry. Prog Histochem Cytochem 47 (2012), 61–132.
24. 24 Baccouche, H., Maunz, M., Beck, T., et al. Differentiating cardiac amyloidosis and hypertrophic cardiomyopathy by use of three-dimensional speckle tracking echocardiography. Echocardiography 29 (2012), 668–677.
25. 25 Cappelli, F., Baldasseroni, S., Bergesio, F., et al. Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis. Clin Cardiol 38 (2015), 69–75.
26. 26 Quarta, C.C., Solomon, S.D., Uraizee, I., et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation 129 (2014), 1840–1849.
27. 27 Ng, B., Connors, L.H., Davidoff, R., Skinner, M., Falk, R.H., Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated (AL) amyloidosis. Arch Intern Med 165 (2005), 1425–1429.
28. 28 Engvall, C., Henein, M., Holmgren, A., et al. Can myocardial strain differentiate hypertrophic from infiltrative etiology of a thickened septum?. Echocardiography 28 (2011), 408–415.
29. 29 Bhuiyan, T., Helmke, S., Patel, A.R., et al. Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS). Circ Heart Fail 4 (2011), 121–128.
30. 30 Milani, P., Dispenzieri, A., Gertz, M.A., et al. In patients with light-chain (AL) amyloidosis myocardial contraction fraction (MCF) is a simple, but powerful prognostic measure that can be calculated from a standard echocardiogram (ECHO) [abstract]. Blood, 126, 2015, 1774.
31. 31 Tendler, A., Helmke, S., Teruya, S., Alvarez, J., Maurer, M.S., The myocardial contraction fraction is superior to ejection fraction in predicting survival in patients with AL cardiac amyloidosis. Amyloid 16 (2014), 1–6.
32. 32 Kula, R.W., Engel, W.K., Line, B.R., Scanning for soft-tissue amyloid. Lancet 1 (1977), 92–93.
33. 33 Sobol, S.M., Brown, J.M., Bunker, S.R., Patel, J., Luli, R.J., Noninvasive diagnosis of cardiac amyloidosis by technetium-99m-pyrophosphate myocardial scintigraphy. Am Heart J 103 (1982), 563–566.
34. 34 Perugini, E., Guidalotti, P.L., Salvi, F., et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 46 (2005), 1076–1084.
35. 35 Bokhari, S., Castano, A., Pozniakoff, T., et al. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 6 (2013), 195–201.
36. 36 Rapezzi, C., Quarta, C.C., Guidalotti, P.L., et al. Role of 99mTc-PYP scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 4 (2011), 659–670.
37. 37 Castaño A, DeLuca A, Weinberg R, et al. Serial scanning with technetium pyrophosphate (99mTc-PYP) in advanced ATTR cardiac amyloidosis. J Nucl Cardiol, http://dx.doi.org/10.1007/s12350-015-0261-x, accessed May 5, 2016.
38. 38 Narotsky, D.L., Kodali, S.K., Maurer, M.S., et al. Screening for transthyretin cardiac amyloidosis using 99mTc-pyrophosphate scintigraphy in patients undergoing transcatheter aortic valve replacement [abstract]. Circulation, 132, 2015, A13456.
39. 39 Grothues, F., Smith, G.C., Moon, J.C., et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 90 (2002), 29–34.
40. 40 Codella, N.C., Weinsaft, J.W., Cham, M.D., et al. Left ventricle: automated segmentation by using myocardial effusion threshold reduction and intravoxel computation at MR imaging. Radiology 248 (2008), 1004–1012.
41. 41 Codella, N.C., Lee, H.Y., Fieno, D.S., et al. Improved left ventricular mass quantification with partial voxel interpolation: in vivo and necropsy validation of a novel cardiac MRI segmentation algorithm. Circ Cardiovasc Imaging 5 (2012), 137–146.
42. 42 White, J.A., Kim, H.W., Shah, D., et al. CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis. JACC Cardiovasc Imaging 7 (2014), 143–156.
43. 43 Banypersad, S.M., Sado, D.M., Flett, A.S., et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging 6 (2013), 34–39.
44. 44 Austin, B.A., Tang, W.H., Rodriguez, E.R., et al. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging 2 (2009), 1369–1377.
45. 45 Maceira, A.M., Joshi, J., Prasad, S.K., et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111 (2005), 186–193.
46. 46 Fontana, M., Pica, S., Reant, P., et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 132 (2015), 1570–1579.
47. 47 Dungu, J.N., Valencia, O., Pinney, J.H., et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging 7 (2014), 133–142.
48. 48 Fontana, M., Banypersad, S.M., Treibel, T.A., et al. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging 7 (2014), 157–165.
49. 49 Barison, A., Aquaro, G.D., Pugliese, N.R., et al. Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging. J Intern Med 277 (2015), 605–614.
50. 50 Fontana, M., Banypersad, S., Treibel, T.A., et al. AL and ATTR cardiac amyloid are different: native T1 mapping and ECV detect different biology [abstract]. J Cardiovasc Magn Reson, 16(suppl 1), 2014, P341.
51. 51 Fontana, M., Banypersad, S.M., Treibel, T.A., et al. Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: a cardiac MR imaging study. Radiology 277 (2015), 388–397.
52. 52 ASNC Practice Points. 99mTechnetium-pyrophosphate imaging for transthyretin cardiac amyloidosis. Available at: http://www.asnc.org/Files/Practice%20Resources/Practice%20Points/ASNC%20Practice%20Point-99mTechnetiumPyrophosphateImaging2016.pdf. Accessed March 2, 2016.
53. 53 Gillmore, J.D., Maurer, M.S., Falk, R.H., et al. Non-biopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133 (2016), 2404–2412.